These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 31109352)

  • 1. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.
    Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H
    Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile.
    Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; ; Ruland A; Speel EJM; Dingemans AMC
    Lung Cancer; 2019 Dec; 138():102-108. PubMed ID: 31678831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study of Rb1, cyclin D1 and p16 immunohistochemistry expression to distinguish lung small-cell carcinoma and large-cell neuroendocrine carcinoma.
    Papaxoinis G; Bille A; McLean E; Nonaka D
    Histopathology; 2022 Aug; 81(2):205-214. PubMed ID: 35544410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
    Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
    Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TTF-1 and c-MYC-defined Phenotypes of Large Cell Neuroendocrine Carcinoma and Delta-like Protein 3 Expression for Treatment Selection.
    Miyagawa-Hayashino A; Okada S; Takeda-Miyata N; Takashima Y; Yamada T; Takemura Y; Uchino J; Inoue M; Takayama K; Konishi E
    Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):313-320. PubMed ID: 33031101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.
    Saunders LR; Bankovich AJ; Anderson WC; Aujay MA; Bheddah S; Black K; Desai R; Escarpe PA; Hampl J; Laysang A; Liu D; Lopez-Molina J; Milton M; Park A; Pysz MA; Shao H; Slingerland B; Torgov M; Williams SA; Foord O; Howard P; Jassem J; Badzio A; Czapiewski P; Harpole DH; Dowlati A; Massion PP; Travis WD; Pietanza MC; Poirier JT; Rudin CM; Stull RA; Dylla SJ
    Sci Transl Med; 2015 Aug; 7(302):302ra136. PubMed ID: 26311731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
    Rudin CM; Pietanza MC; Bauer TM; Ready N; Morgensztern D; Glisson BS; Byers LA; Johnson ML; Burris HA; Robert F; Han TH; Bheddah S; Theiss N; Watson S; Mathur D; Vennapusa B; Zayed H; Lally S; Strickland DK; Govindan R; Dylla SJ; Peng SL; Spigel DR;
    Lancet Oncol; 2017 Jan; 18(1):42-51. PubMed ID: 27932068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging with [
    Tendler S; Dunphy MP; Agee M; O'Donoghue J; Aly RG; Choudhury NJ; Kesner A; Kirov A; Mauguen A; Baine MK; Schoder H; Weber WA; Rekhtman N; Lyashchenko SK; Bodei L; Morris MJ; Lewis JS; Rudin CM; Poirier JT
    Lancet Oncol; 2024 Aug; 25(8):1015-1024. PubMed ID: 38950555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors.
    Xie H; Boland JM; Maleszewski JJ; Aubry MC; Yi ES; Jenkins SM; Koepplin JW; Terra SBSP; Mansfield AS; Roden AC
    Lung Cancer; 2019 Sep; 135():73-79. PubMed ID: 31447005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DLL3 expression is a predictive marker of sensitivity to adjuvant chemotherapy for pulmonary LCNEC.
    Ogawa H; Sakai Y; Nishio W; Fujibayashi Y; Nishikubo M; Nishioka Y; Tane S; Kitamura Y; Sudo T; Sakuma T; Yoshimura M
    Thorac Cancer; 2020 Sep; 11(9):2561-2569. PubMed ID: 32691982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
    Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
    Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular markers help characterize neuroendocrine lung tumors.
    Rusch VW; Klimstra DS; Venkatraman ES
    Ann Thorac Surg; 1996 Sep; 62(3):798-809; discussion 809-10. PubMed ID: 8784011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of a deep learning algorithm to distinguish large cell neuroendocrine from small cell lung carcinoma in cytology specimens.
    Gonzalez D; Dietz RL; Pantanowitz L
    Cytopathology; 2020 Sep; 31(5):426-431. PubMed ID: 32246504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases.
    Jiang SX; Kameya T; Shoji M; Dobashi Y; Shinada J; Yoshimura H
    Am J Surg Pathol; 1998 May; 22(5):526-37. PubMed ID: 9591721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancer.
    Huang L; Feng Y; Xie T; Zhu H; Tang L; Shi Y
    BMC Cancer; 2023 Apr; 23(1):312. PubMed ID: 37020179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
    Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M
    Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma.
    Burns L; Tukachinsky H; Raskina K; Huang RSP; Schrock AB; Sands J; Kulke MH; Oxnard GR; Tapan U
    Lung Cancer; 2024 Feb; 188():107454. PubMed ID: 38159439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma.
    Matsumura Y; Umemura S; Ishii G; Tsuta K; Matsumoto S; Aokage K; Hishida T; Yoshida J; Ohe Y; Suzuki H; Ochiai A; Goto K; Nagai K; Tsuchihara K
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2159-70. PubMed ID: 25989941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical differential diagnosis between large cell neuroendocrine carcinoma and small cell carcinoma by tissue microarray analysis with a large antibody panel.
    Nitadori J; Ishii G; Tsuta K; Yokose T; Murata Y; Kodama T; Nagai K; Kato H; Ochiai A
    Am J Clin Pathol; 2006 May; 125(5):682-92. PubMed ID: 16707368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung: differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma.
    Isaka M; Nakagawa K; Ohde Y; Okumura T; Watanabe R; Ito I; Nakajima T; Kondo H
    Eur J Cardiothorac Surg; 2012 Apr; 41(4):841-6. PubMed ID: 22219429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.